Loading...
•
Jun 30
QIAGEN Q2 2025 Earnings Report
QIAGEN exceeded expectations in Q2 2025 with strong revenue growth and improved profitability.
Key Takeaways
QIAGEN delivered a solid Q2 2025, with revenues rising 7% year-over-year to $534 million and adjusted EPS reaching $0.60. Diagnostic solutions drove double-digit growth, and operating margins improved through efficiency gains.
Revenue grew 7% year-over-year to $534 million, exceeding guidance.
Adjusted EPS reached $0.60, ahead of expectations.
Adjusted operating margin rose to 29.9%, up from 28.4% last year.
Diagnostic solutions, led by QIAstat-Dx and QuantiFERON, showed strong double-digit growth.
QIAGEN
QIAGEN
Forward Guidance
QIAGEN raised its full-year 2025 net sales outlook while reaffirming adjusted EPS targets, citing strong business momentum and efficiency gains.
Positive Outlook
- Full-year 2025 net sales outlook increased to 4-5% CER (from ~4%).
- Core sales growth forecast raised to 5-6% CER (from ~5%).
- Adjusted EPS guidance reaffirmed at $2.35 CER.
- Strong performance in QIAstat-Dx and QuantiFERON expected to continue.
- Planned launch of three new instruments in late 2025 to support future growth.
Challenges Ahead
- Impact of new tariffs factored into outlook.
- Macroeconomic trends, including U.S. and China import tariffs, pose ongoing risks.
- Continued pressure from discontinued product lines like NeuMoDx and Dialunox.
- No specific net income figure disclosed for the quarter.
- Limited geographic revenue data available for detailed segmentation.